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Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly pathogenic
novel coronavirus that has caused a worldwide outbreak. Here we describe a reverse tran-
scription loop-mediated isothermal amplification (RT-LAMP) assay that uses a portable
device for efficient detection of SARS-CoV-2. This RT-LAMP assay specifically detected
SARS-CoV-2 without cross-reacting with the most closely related human coronavirus,
SARS-CoV. Clinical evaluation of nasal swab samples from suspected SARS-CoV-2 pneu-
monia (COVID-19) patients showed that the assay could detect over 23.7 copies within 15
min with a 100% probability. Since the RT-LAMP assay can be performed with a portable
battery-supported device, it is a rapid, simple, and sensitive diagnostic assay for COVID-19
that can be available at point-of-care. We also developed the RT-LAMP assay without the
RNA extraction step–Direct RT-LAMP, which could detect more than 1.43 x 103 copies
within 15 min with a 100% probability in clinical evaluation test. Although the Direct RT-
LAMP assay was less sensitive than the standard RT-LAMP, the Direct RT-LAMP assay
can be available as the rapid first screening of COVID-19 in poorly equipped areas, such as
rural areas in developing countries.
Author summary
Rapid, accurate and simple diagnostic assay is required to provide an appropriate treat-
ment and establish a surveillance system to prevent the spread of COVID-19. In this
study, we developed the RT-LAMP assay using a portable platform equipped with a bat-
tery for detection of SARS-CoV-2 in clinical specimens. It could detect over 23.7 copies
within 15 min. Since RNA extraction step is one of the main obstacles for rapid diagnosis,
we also developed the RT-LAMP assay without this step, Direct RT-LAMP. This assay
could detect over 203 copies of viral RNA in virus-spiked swab solution within 10.5 min.
Since our RT-LAMP assay is a rapid, simple and highly sensitive diagnostic system for
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Introduction
In December 2019, an outbreak of pneumonia caused by a novel coronavirus, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China [1,2].
SARS-CoV-2 has rapidly spread worldwide, and the World Health Organization (WHO) has
declared the corona virus disease (COVID-19) as a pandemic on 11 March 2020 [3]. Until the
day of the announcement, over 4,962,707 confirmed cases of SARS-CoV-2 pneumonia in at
least 200 countries of all continents, except Antarctica, had been reported [4].
COVID-19 is usually characterized by fever, cough, and myalgia or fatigue, and shows a
mortality of 3.4% with progressive respiratory failure or multiple organ failure [5]. The median
incubation period of COVID-19 is 5.1 days in 50 provinces, regions, and countries outside
Wuhan, Hubei province, China [6]. However, several reports described that SARS-CoV-2 may
show a longer incubation period (~19 days) and human-to-human transmission in the incuba-
tion period, making difficult to prevent the infection from spreading [7]. The transmission
mechanism of SARS-CoV-2 has not been fully elucidated, although it shows a highly commu-
nicable ability through aerosol droplets [8]. Currently, early detection of SARS-CoV-2 and
adequate isolation of patients are the most effective countermeasures to prevent human-to-
human transmission of the virus. Therefore, development of an on-site, rapid, and sensitive
diagnostic assay for SARS-CoV-2 infections is of top priority to provide an appropriate treat-
ment and establish a surveillance system to prevent the spread of COVID-19.
SARS-CoV-2 infection is diagnosed in the laboratory mainly using nucleic acid amplification
tests (NAATs). Several reverse transcription-quantitative PCR (RT-qPCR) assays were developed
by WHO soon after the report of genome sequences of SARS-CoV-2, and are currently the gold
standard to detect virus-specific RNA [9]. However, RT-qPCR requires a step of viral RNA extrac-
tion prior to the test and the use of a qPCR thermal cycler instrument connected to stable electric
power. Moreover, there is potential risk of viral RNA degradation during sample transport to the
laboratory due to inappropriate storage conditions. Thus, novel diagnostic technologies that can
be conducted at the point-of-care, including rural areas of developing countries in which stable
electricity may be unavailable, are crucial to control and monitor SARS-CoV-2 infections.
Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is a rapid and
sensitive RNA detection method performed under simple isothermal conditions using four or
six target sequence-specific oligonucleotide primers [10]. Since LAMP reactions can be per-
formed using a battery-driven portable equipment, RT-LAMP assay is suitable for on-site
diagnosis even in insufficiently equipped facilities. We have previously developed RT-LAMP
assays for Ebola and Zika viruses in response to recent outbreaks of associated diseases, and
the assays have been deployed for field surveillance in Guinea and Brazil, respectively [11–13].
Here, we report an RT-LAMP assay specific for SARS-CoV-2 with a comparable sensitivity to
standard RT-qPCR. This assay shows a potential to be performed without the RNA extraction
step, representing a rapid and simple diagnostic NAAT.
Materials and methods
Ethics statement
This study was approved by the Institutional Review Boards of Nagasaki University (approval
no. 200409234).
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Viral RNA and synthesized standard RNA
Viral RNA of SARS-CoV-2 and SARS-CoV were kindly provided by the Japanese National
Institute of Infectious Diseases (NIID), and Dr. Koichi Morita from the Nagasaki University,
Japan, respectively. To calculate the copy number of viral genome detection in both LAMP
and quantitative PCR (qPCR) assays, synthesized RNAs were prepared using T7 RiboMAX
Express Large Scale RNA Production System (Promega) with the artificially synthesized DNA
of the viral target sequence conjugated with the T7 promoter sequence.
LAMP primer design
LAMP primers for SARS-CoV-2 detection were designed based on the sequences of the
ORF1b region of the virus. The SARS-CoV-2 sequences available in GenBank and GISAID
were aligned using BioEdit 7.0.5.3 software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html)
to identify conserved regions. A consensus sequence of the ORF1b region was used to design
LAMP primers through Primer Explorer V5 software (Eiken; http://primerexplorer.jp/). The
RT-LAMP assay requires a set of 6 primers: 2 outer primers (F3 and B3), 2 inner primers (FIP
and BIP), and 2 loop primers (LF and LB). FIP consists of a complementary sequence of F1
and a sense sequence of F2, whereas BIP includes a complementary sequence of B1 and a sense
sequence of B2 (10). The detailed primer sequences used for SARS-CoV-2 amplification are
shown in Table 1.
RT-LAMP assay
RT-LAMP was performed with Isothermal Master mix reagent ISO-004 (Canon medical sys-
tems) using the Genelyzer FIII real-time fluorescence detection platform (Canon medical sys-
tems). The reaction mixture (total volume = 25 μL) contained 15 μL of Isothermal Master Mix,
1 U of AMV Reverse Transcriptase (Nippon gene), 20 pmol (each) of FIP and BIP primers, 5
pmol (each) of F3 and B3 outer primers, 10 pmol (each) of F and B loop primers, and 5 μL of
RNA sample (template). The reaction was performed at the following conditions: for the
ORF1b-1 primer set, 68˚C for 20 min, followed by a dissociation analysis at 95˚C–75˚C with
the temperature change rate of 0.1˚C/s; for the ORF1b-2 primer set, 67˚C for 20 min, followed
by a similar dissociation analysis. Extracted RNA from samples or heat inactivated swab sam-
ples were used as a template. Synthesized RNAs containing the target sequence of the LAMP
Table 1. Sequences of LAMP primers.
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assay were used as positive controls. Nonspecific amplification was excluded by comparing the
melting temperature to that of the positive control [13].
RT-qPCR assay
RT-qPCR was performed using the One Step PrimeScript III RT-qPCR Mix (Takara Bio) as
reported previously [14]. The reaction mixture (total volume = 20 μL) contained 10 μL of 2×
One Step PrimeScript III RT-qPCR Mix, 0.4 μL of ROX Reference Dye, 2 μL of 10× primer-
probe mixture, 2 μL of RNA sample, and 5.6 μL of RNase-free water. Two different sets of
primer-probe mixture were used in this study. The first set was developed by NIID (NIID-
qPCR) and used with the final concentration of 500 nM, 700 nM, and 200 nM of the forward
primer, reverse primer, and FAM-labeled probe, respectively [15]. The second primer-probe
set was reported by WHO for detection of E gene of SARS-CoV-2 and SARS (WHO-qPCR),
and used 400 nM of each primer and 200 nM of the probe [9]. The NIID-qPCR reaction was
performed using the StepOnePlus instrument (Applied Biosystems) with a thermal cycle pro-
gram of 52˚C for 5 min, 95˚C for 10 sec, followed by 45 cycles of 95˚C for 5 sec, and 60˚C for
30 sec WHO-qPCR was performed with the same program. Cut-off values were set at the
threshold cycle (Ct) value of 40. To quantify viral RNA, a standard curve was generated with
10-fold serial dilutions of synthesized standard RNA of the qPCR target sequences.
Validation of the assays using clinical specimens
A validation study was performed using 224 nasal swab samples collected in Nagasaki prefec-
ture, Japan, without any clinical information. For RT-LAMP and RT-qPCR, RNA was
extracted using QIAamp Viral RNA Mini Kit (QIAGEN) according to the instructions of the
manufacturer. For Direct RT-LAMP, the samples were heated at 95˚C for 10 min for inactiva-
tion of SARS-CoV-2. Aliquots of 5 μL of RNA samples or heat inactivated swab samples were
used for the LAMP assay with ORF1b-1 primer set and RT-qPCR with NIID primer set.
Results
Sensitivity of RT-LAMP assay using in vitro synthesized RNA
We designed two SARS-CoV-2 specific LAMP primer sets that targeted conserved sequences
in the ORF1b region (name: ORF1b-1 and ORF1b-2) (Table 1). To examine the sensitivity of
the RT-LAMP assay for SARS-CoV-2, serial 10-fold dilutions of in vitro synthesized RNA pos-
sessing the target sequence of Wuhan-Hu-1 strain were used as template. All (6/6) or 83% (5/
6) of the reactions with 50 copies of RNA yielded positive results with ORF1b-1 (RT-LAMP/
ORF1b-1) or ORF 1b-2 primer sets (RT-LAMP/ORF1b-2), respectively (Table 2). Addition-
ally, RT-LAMP/ORF1b-1 could detect samples containing 5 RNA copies once in six replicates.
Moreover, both RT-LAMP/ORF1b-1 and RT-LAMP/ORF1b-2 could detect 500 RNA copies
within 8 min and 50 RNA copies within 11.8 min (Table 2). These results indicate that this
RT-LAMP assay can be used as a rapid and sensitive test for the detection of SARS-CoV-2
RNA.
Specificity of RT-LAMP assay
Following this, to examine the specificity of the RT-LAMP assay, we performed the assay using
RNAs extracted from SARS-CoV, which is the most closely related human coronavirus to
SARS-CoV-2, and SARS-CoV-2 (n = 2 for each viral RNA). The RT-LAMP did not detect
SARS-CoV RNA regardless of the primer set used, while SARS-CoV-2 RNA was successfully
detected with both primer sets (Table 3). We confirmed the presence of SARS-CoV RNA
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using RT-qPCR with WHO primer (Table 3, Ct = 27.5 (7,780 copies) and 27.7 (6,890 copies)
in duplicated samples). These results indicate that our RT-LAMP assay is highly specific for
SARS-CoV-2.
Sensitivity comparison between RT-LAMP assay and RT-qPCR assay
To compare the sensitivity of RT-LAMP/ORF1b-1, RT-LAMP/ORF1b-2, and RT-qPCR assays
using the NIID (RT-qPCR/NIID) or the WHO (RT-qPCR/WHO) primer sets, we prepared
10-fold serial dilutions of viral RNA extracted from SARS-CoV-2 JPN/TY/WK-521 strain
(GISAID: EPI-ISL-408667). All RT-LAMP and RT-qPCR assays could detect the viral RNA in
all samples of dilutions lower than 10−4 (Table 4). The average detection time of RT-LAMP
assays was 12.8 min. The Ct values of the RT-qPCR/NIID and RT-qPCR/WHO for 10−4 dilu-
tion samples were 37.75±0.21 and 35.81±0.19, which corresponded to 15.9±2.2 and 26.7±4.0
copies per reaction, respectively (Table 4). In addition, RT-qPCR/NIID and RT-qPCR/WHO
assays detected the 10−5 dilution of the viral RNA samples twice and once in 3 replicates,
respectively. Furthermore, the RT-LAMP/ORF1b-1 assay also detected the 10−5 virus dilution
once in 3 replicates; although, the RT-LAMP/ORF1b-2 failed to detect these samples (Table 4).
The 10−5 dilution was estimated to include 5.6 copies in RT-qPCR/NIID and 2.6 copies in RT-
qPCR/WHO (Table 4). Taken together, these results indicate that the RT-LAMP/ORF1b-1
assay has almost the same sensitivity as RT-qPCR assay, which is a highly sensitive detection
method.
Evaluation of RT-LAMP assay without RNA extraction step
In most cases, genome analysis for detection of RNA viruses requires a step of RNA extraction
from clinical specimens. Since this step usually takes about 30 min, it is one of the main
Table 2. Sensitivity and detection time of RT-LAMP assay.
ORF1b-1
Copies/reaction 500 50 5 Water
Time (min) 7.5 9.0 - -
7.3 8.8 10.5 -
8.0 11.8 - -
6.8 9.3 -
6.8 9.0 - -
7.3 8.5 - -
Average 7.3 9.4 - -
SD 0.4 1.1 - -
Positive 6/6 6/6 1/6 0/6
ORF1b-2
Copies/ reaction 500 50 5 Water
Time (min) 8.0 11.8 - -
7.8 - - -
7.3 11.5 - -
7.5 9.0 - -
7.3 9.5 - -
6.8 10.3 - -
Average 7.4 10.4 - -
SD 0.4 1.1 - -
Positive 6/6 5/6 0/6 0/6
https://doi.org/10.1371/journal.pntd.0008855.t002
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obstacles for rapid diagnosis. Therefore, the feasibility of the RT-LAMP assay without RNA
extraction for clinical specimens was evaluated using human nasal and oral mixed swab sus-
pensions spiked with SARS-CoV-2 JPN/TY/WK-521 strain. We prepared the nasal and oral
mixed swab samples with 10-fold serial dilutions of SARS-CoV-2. These mixed swab samples
Table 3. Specificity of RT-LAMP assay.
Primer set SARS SARS-CoV-2
RT-LAMP(min) ORF1b-1 - - + (11.5)
ORF1b-2 - - + (9.75)
RT-qPCR (Ct) WHO + (27.5) + (27.7)
https://doi.org/10.1371/journal.pntd.0008855.t003
Table 4. Comparison of sensitivity between RT-qPCR and RT-LAMP assays.
Dilution rate of viral RNA
10−2 10−3 10−4 10−5 Water
RT-LAMP ORF1b_1 Time (min) 6.5 7.8 9.0 - -
6.3 7.3 9.0 9.5 -
6.5 7.8 12.8 - -
Average 6.4 7.6 10.3 - -
SD 0.1 0.2 1.8 - -
Positive 3/3 3/3 3/3 1/3 0/3
ORF1b_2 Time (min) 6.8 7.5 9.5 - -
6.0 7.8 10.8 - -
6.8 7.5 10.5 - -
Average 6.5 7.6 10.3 - -
SD 0.4 0.1 0.5 - -
Positive 3/3 3/3 3/3 0/3 0/3
RT-qPCR NIID Ct value 30.93 34.08 37.59 39.08 -
30.79 34.12 38.05 39.34 -
30.60 33.79 37.61 - -
Average 30.77 34.00 37.75 39.21 -
SD 0.14 0.15 0.21 0.13 -
copies/ reaction 2036.9 214.4 17.5 6.1 -
2249.6 208.6 12.7 5.0 -
2577.0 264.4 17.3 - -
Average 2287.8 229.1 15.9 5.6 -
SD 222.1 25.0 2.2 0.5 -
Positive 3/3 3/3 3/3 2/3 0/3
WHO Ct value 29.31 32.80 35.96 38.93 -
29.23 32.72 35.94 - -
29.41 32.79 35.55 - -
Average 29.32 32.77 35.81 38.93 -
SD 0.07 0.03 0.19 0.00 -
copies/ reaction 3503.2 254.9 23.7 2.6 -
3694.3 269.0 24.1 - -
3246.6 256.5 32.4 - -
Average 3481.4 260.2 26.7 2.6 -
SD 183.5 6.3 4.0 0.0 -
Positive 3/3 3/3 3/3 1/3 0/3
https://doi.org/10.1371/journal.pntd.0008855.t004
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were heated at 95˚C for 10 min for inactivation of SARS-CoV-2. We conducted RT-LAMP/
ORF1b-1 and RT-qPCR/NIID assays with the heat inactivated swab samples, which we named
“Direct RT-LAMP” and “Direct RT-qPCR,” respectively. Simultaneously, we also conducted
RT-LAMP/ORF1b-1 and RT-qPCR/NIID assays using RNAs extracted from the nasal and
oral mixed swab samples spiked with SARS-CoV-2 as reference tests. Sample viral dilutions
ranging from 10−2 to 10−6 dilution were detected within 10.5 min in both RT-LAMP and
Direct RT-LAMP (Table 5). Furthermore, both Direct RT-LAMP and RT-LAMP could detect
10−7 diluted virus samples with 33% probability; nevertheless, RT-qPCR could efficiently
detect these samples. In this swab spike tests, both assays have same sensitivity. However, the
detection time for Direct RT-LAMP is longer than that of RT-LAMP (mean 0.75 min). There-
fore, composition of swab samples may affect the efficiency of genome amplification in
RT-LAMP assay. Standard RT-qPCR using extracted RNA indicated that 10−6 and 10−7 dilu-
tion include 203 ± 21.4 and 12.8 ± 4.78 copies of viral RNA per reaction, respectively. Taken
together, these results suggest that Direct RT-LAMP assay can be used as a rapid and sensitive
diagnostic test for SARS-CoV-2.
Evaluation of RT-LAMP assay using clinical specimens
To evaluate the diagnostic accuracy of RT-LAMP and Direct RT-LAMP, we analyzed 224
nasal swab samples from suspected COVID-19 patients using these experimental protocols at
the same time has RT-qPCR/NIID as reference test. Sixteen samples were suspended in Hank’s
Balanced Salt Solution (HBSS) and the remaining samples were suspended in phosphate-buff-
ered saline (PBS) solution.
As shown in Fig 1, the detection time of RT-LAMP and Direct RT-LAMP was significantly
correlated with copy number of SARS-CoV-2 RNA (Peason’s correlation (r) = -0.25 and -0.22,
for RT-LAMP and Direct RT-LAMP, respectively). This correlation indicates that viral RNA cop-
ies in clinical samples could be roughly estimated from the detection time of RT-LAMP assay.
The detection time for Direct RT-LAMP using PBS-suspended samples PBS was delayed on
average by only 0.45 min compared with RT-LAMP using extracted RNA (Fig 2). In contrast,
the detection time of Direct RT-LAMP using HBSS-suspended swab samples was 3 to 8 min
(mean 4.8 min) later than that of RT-LAMP using extracted RNA (Fig 2), suggesting that
HBSS is not appropriate as swab sample suspension solution for Direct RT-LAMP. Therefore,
the results of the 16 samples suspended in HBSS were excluded from the analysis (Table 6).
A total of 126 samples were deemed positive by the reference RT-qPCR assay. In this evalu-
ation test, the RNA amount of each clinical sample was estimated to be in the range from 1.3
to 6.88 x 107 copies per reaction. The RT-LAMP/ORF1b-1 assay detected all clinical samples
that had more than 23.7 copies of viral RNA as positive for SARS-CoV-2 with 100% probability
(Table 6 and S1 Table). Detection probabilities of the assay were 50% for 10–19.8 copies and
67% for less than 10 copies. All positive results were obtained within 14.5 min (Fig 1A and S1
Table). The Direct RT-LAMP with ORF1b-1 primer set detected samples that had more than
1.43 x 103 copies of viral RNA with 100% probability (Table 6 and S2 Table). The assay still
showed 53% and 10% probabilities for 102−103 and 101−102 viral copies, respectively. The
minimum copy numbers which were possible to detect was 70.8 copies (S2 Table). For samples
that had 7.08 x 101−1.41 x 103 viral copies, composition of swab samples seem to affect the
results; although, the results were consistent with those from Direct RT-LAMP for swab sam-
ples spiked with the virus (Table 5). Therefore, it should be carefully noted that low viral RNA
copy numbers may not be detected by this Direct RT-LAMP assay depending on the composi-
tion of the sample. And, this Direct RT-LAMP assay cannot be used to prove a negative result
for SARS-CoV-2 infection.
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Discussion
In this study, we developed a rapid and sensitive diagnostic assay for SARS-CoV-2 infections,
which is based on RT-LAMP. The assay could detect 23.7 copies of viral RNA within 15 min
from clinical specimens (Fig 1A, Table 6, and S1 Table). Currently, RT-qPCR is the gold stan-
dard assay of COVID-19 diagnosis and takes at least 2–3 hours to complete all processes
including RNA extraction followed by a quantitative PCR step using a real-time thermal cycler.
To shorten the assay time, several research groups developed RT-LAMP assays against SARS--
CoV-2 [16–21]; however, the detection sensitivity and assay time can be improved. Huang
et al. reported a novel RT-LAMP assay that could detect 2 copies of viral RNA after an addi-
tional gel electrophoresis step, requiring more assay time than the normal RT-LAMP method
Table 5. Evaluation of RT-LAMP assay without RNA extraction step.
Dilution rate of virus
Template 10−2 10−3 10−4 10−5 10−6 10−7 Water
Direct RT-LAMP Swab solution Time (min) 5.5 6.0 6.8 7.5 10.5 - -
5.3 6.0 6.8 7.3 9.0 10.5 -
5.5 6.0 7.3 7.5 9.0 - -
Average 5.4 6.0 6.9 7.4 9.5 - -
SD 0.1 0.0 0.2 0.1 0.7 - -
Positive 3/3 3/3 3/3 3/3 3/3 1/3 0/3
RT-LAMP RNA Time (min) 4.3 5.0 5.8 6.5 7.3 - -
5.5 6.0 7.3 7.5 9.0 - -
4.8 5.8 6.3 6.8 7.5 9.5 -
Average 4.8 5.6 6.4 6.9 7.9 - -
SD 0.5 0.4 0.6 0.4 0.8 - -
Positive 3/3 3/3 3/3 3/3 3/3 1/3 0/3
Direct RT-qPCR Swab solution Ct value 23.14 26.47 29.86 33.43 36.40 - -
23.22 26.50 29.87 33.29 36.93 - -
23.01 26.46 29.75 33.28 36.96 - -
Average 23.12 26.48 29.83 33.34 36.76 - -
SD 0.09 0.02 0.05 0.07 0.26 - -
copies/ reaction 1.14× 106 9.07×104 6.92×103 4.62×102 4.87×101 - -
1.06× 106 8.84×104 6.89×103 5.12×102 3.25×101 - -
1.25× 10−6 9.15×104 7.50×103 5.17×102 3.17×101 - -
Average 1.15×106 9.02×104 7.10×104 4.97×102 3.77×101 - -
SD 7.73×104 1.30×103 2.81×102 2.49×101 7.85×100 - -
Positive 3/3 3/3 3/3 3/3 3/3 0/3 0/3
RT-qPCR RNA Ct value 20.89 24.29 27.76 31.13 34.70 38.95 -
20.97 24.34 27.80 31.18 34.35 37.66 -
20.75 24.28 27.65 31.00 34.51 38.16 -
Average 20.87 24.30 27.74 31.10 34.52 38.26 -
SD 0.09 0.03 0.07 0.07 0.14 0.53 -
copies/ reaction 6.23×106 4.75×105 3.41×104 2.64×103 1.77×102 7.03×100 -
5.85×106 4.56×105 3.29×104 2.55×103 2.29×102 1.87×101 -
6.93×106 4.77×105 3.72×104 2.92×103 2.04×102 1.28×101 -
Average 6.33×106 4.69×105 3.47×104 2.71×103 2.03×102 1.28×101 -
SD 4.45×105 9.44×104 1.78×103 1.56×102 2.14×101 4.78×100 -
Positive 3/3 3/3 3/3 3/3 3/3 3/3 0/3
https://doi.org/10.1371/journal.pntd.0008855.t005
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[21]. In addition to RT-LAMP, we also developed a remarkable rapid assay, Direct RT-LAMP,
that does not require the extraction of viral RNA from clinical specimens. This assay could
detect 203 copies of viral RNA in the virus-spiked swab solution within 10.5 min (Table 5).
The LAMP method has an excellent specificity accomplished by 6 to 8 different primer bind-
ing regions in the target DNA sequence. Nevertheless, several viruses require multiple sets of
Fig 1. Detection time of SARS-CoV-2 RNA from clinical specimens with the RT-LAMP and Direct RT-LAMP
assays. Detection time of clinical samples determined by RT-LAMP/ORF1b-1 (A) and Direct RT-LAMP/ORF1b-1 (B)
were plotted to viral RNA copy numbers per reaction with reference RT-qPCR/NIID. The samples suspended by PBS
or HBSS are shown as blue or red dots, respectively.
https://doi.org/10.1371/journal.pntd.0008855.g001
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primers to detect whole lineages/genotypes due to genetic diversity of their genome sequences.
Lassa virus (LASV) has 6 lineages and has highly diverse genome even within the same lineage.
There is a single report of a RT-LAMP assay for LASV, and the assay requires 3 sets of primers
to detect only lineage II [22]. Zika virus also shows diversity in genome sequences between
Asian and African genotypes, requiring the mixture of 2 primer sets to detect all strains in one
reaction [13]. Fortunately, SARS-CoV-2 shows lower genetic diversity worldwide, and there-
fore would be suitable to be diagnosed using the simple RT-LAMP assay with one primer set
(S1 Fig).
Before the emergence of SARS-CoV-2, two large outbreaks of novel coronavirus diseases
were reported: severe acute respiratory syndrome (SARS) in 2002, and Middle East respiratory
syndrome (MERS) in 2012 [23,24]. For the molecular diagnosis for these diseases, RT-PCR
and RT-qPCR were used as gold standard assays with an immediate announcement of recom-
mended protocols by WHO. Several years since the emergence of these coronavirus diseases,
RT-LAMP assays were developed for faster diagnosis [25,26]. For SARS, Thai et al. developed
Fig 2. Comparison of detection time between RT-LAMP and Direct RT-LAMP. The delay time of detection by
Direct RT-LAMP is shown for nasal swabs suspended in HBSS and PBS.
https://doi.org/10.1371/journal.pntd.0008855.g002
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a RT-LAMP assay which is 100-fold more sensitive than RT-PCR [25] and showed clear linear-
ity between viral titer and detection time, and that could detect SARS-CoV even in RT-PCR
negative samples. Similar to SARS, several RT-LAMP assays were developed for the detection
of MERS-CoV. Shirato et al. developed a RT-LAMP assay for MERS with a sensitivity compa-
rable to standard RT-qPCR, and with sufficient specificity to distinguish MERS-CoV from 20
other respiratory viruses [26]. These past reports indicate advantages in using RT-LAMP
assays to detect coronavirus from clinical specimens with sufficient sensitivity.
A recent clinical study that evaluated respiratory tract specimens of COVID-19 patients
with severe and mild symptoms showed the initial viral load of 6.17 and 5.11 log10 copies per
mL, respectively [27]. Posterior oropharyngeal saliva, which might represent a non-invasive
reasonable specimen acceptable by patients, contained 4 to 8 log10 copies of viral genome per
mL in the first 5 days from the symptom onset [27]. Similarly, experimental SARS-CoV-2
infection of rhesus monkeys showed that the initial viral load in nasal or throat swabs also con-
tained 4 to 8 log10 copies of viral genome per mL within the first 5 days [28]. Again, our
RT-LAMP assay could detect 23.7 copies of SARS-CoV-2 viral RNA, approximately equivalent
to 1,778 copies per mL in clinical specimens, effectively detecting SARS-CoV-2 in samples
from patients with both severe and mild symptoms during the acute phase. Whereas, our
Direct RT-LAMP is approximately 60-fold less sensitive than RT-LAMP in the assay for clini-
cal specimens, indicating the reliable detection limit of approximately 5 log10 copies per mL
(Table 6). Thus, although this Direct RT-LAMP assay detects SARS-CoV-2 in high viral titer
samples, it should not be used as a sole molecular diagnostic method but used with another
assay such as qPCR to avoid false negatives. Nevertheless, Direct RT-LAMP would signifi-
cantly contribute to the rapid first screening of COVID-19 during an outbreak (1) in the high-
risk population (e.g. pregnant women, individuals with a pre-existing illness) who needs an
immediate care, and (2) in the resource-limited settings where a centrifuge is unavailable. We
also found that HBSS affected the detection time of Direct RT-LAMP (Fig 2), indicating that
HBSS contains inhibitors of RT-LAMP amplification. Therefore, in the Direct RT-LAMP
assay, it is preferable to suspend swab samples in PBS.
Since the RT-LAMP assay can be performed with a portable battery-driven device, it may
be available at point-of-care, even in poorly-equipped settings. Taken together, our results sug-
gest that this new RT-LAMP protocol can be useful as a rapid and sensitive diagnostic assay
for COVID-19, and that the Direct RT-LAMP version could also be made available as a much
simpler, faster, and low-cost assay. These new assays may contribute to public health control
in countries undergoing COVID-19 epidemics, not only for early disease detection, but also to
monitor future expansion of viral infections.
Table 6. Diagnostic accuracy of the RT-LAMP assay and the Direct RT-LAMP assay for SARS-CoV-2 compared with the reference RT-qPCR assay.
RT-LAMP Direct RT-LAMP
Copies/reaction Positive Negative Sensitivity Positive Negative Sensitivity
RT-qPCR Positive >107 2 0 100% 1 0 100%
106−107 17 0 100% 14 0 100%
105−106 24 0 100% 17 0 100%
104−105 18 0 100% 21 0 100%
103−104 18 0 100% 16 1 94%
102−103 18 0 100% 9 8 53%
101−102 12 2 86% 2 18 10%
101> 10 5 67% 0 19 0%
negative 15 67
https://doi.org/10.1371/journal.pntd.0008855.t006
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Supporting information
S1 Table. The detection time of the RT-LAMP assay in clinical samples of less than 100
copies in Table 6.
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S2 Table. The detection time of the Direct RT-LAMP assay in clinical samples of less than
104 copies per reaction.
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S1 Fig. Specificity of LAMP primers. Nucleotide sequences of 40 reference genomes widely
selected from each continent, including the Wuhan-Hu-1 strain, are shown for each primer
binding site. No mutations were observed in all primer binding sites.
(TIF)
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